Scientific article

mTOR Inhibition & Clinical Transplantation: Pancreas & Islet

Published inTransplantation
Publication date2017

This brief overview discusses the beneficial and deleterious effects of mTOR inhibitors on beta-cells, and how sirolimus- and everolimus-based immunosuppression have impacted on practices and outcomes of pancreas and islet transplantation. Sirolimus was the cornerstone of immunosuppressive regimens in islet transplantation at the turn of the millenium, but utilization of mTOR inhibitors has progressively decreased from >80% to <50% of islet transplant recipients in more recent years. For whole pancreas transplantation, mTOR inhibitors were used in approximately 20% of patients in the early 2000s, but this dropped over the years to <10% currently. This decrease is arguably due to less well tolerated side effects without the advantage of better outcomes. Nonetheless, mTOR inhibitors remain extremely valuable as second line immunosuppressants in pancreas and islet transplantation.

Citation (ISO format)
BERNEY, Thierry et al. mTOR Inhibition &amp; Clinical Transplantation: Pancreas &amp; Islet. In: Transplantation, 2017. doi: 10.1097/TP.0000000000001700
Main files (1)
Article (Accepted version)
ISSN of the journal0041-1337

Technical informations

Creation03/02/2017 1:59:00 PM
First validation03/02/2017 1:59:00 PM
Update time03/15/2023 1:36:28 AM
Status update03/15/2023 1:36:28 AM
Last indexation01/16/2024 11:48:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack